截至2024年10月14日，华昊中天医药拥有一种已商业化产品以及19种其他管线候选产品，现有临床试验及项目涵盖晚期乳腺癌、晚期非小细胞肺癌(NSCLC)、乳腺癌新辅助治疗、胃癌、食管癌、乳腺癌脑转移、肺癌脑转移、胶质母细胞瘤及其他实体瘤的适应症。Huahao Zhongtian Medical-B (02563) made its debut on the stock market, with an announced price of HK$16 per share and a total issuance of 14.588 million shares, with 200 shares per lot. The net proceeds are expected to be approximately HK$0.19589 billion. As of the time of this report, it has increased by 34.38% to HK$21.5 with a trading volume of HK$22.4505 million.
According to the Securities Times APP, Huahao Zhongtian Medical-B (02563) made its debut on the stock market, with an announced price of HK$16 per share and a total issuance of 14.588 million shares, with 200 shares per lot. The net proceeds are expected to be approximately HK$0.19589 billion. As of the time of this report, it has increased by 34.38% to HK$21.5 with a trading volume of HK$22.4505 million.
Public information shows that Huahao Zhongtian Pharmaceuticals, established in 2002, is a biomedical company driven by synthetic biology technology. It is dedicated to the development of innovative drugs for tumors and has successfully developed three core technology platforms focusing on the research and development of new drugs from microbial metabolites.
As of October 14, 2024, Huahao Zhongtian Pharmaceuticals has one commercialized product and 19 other pipeline candidate products. Its clinical trials and projects cover indications for late-stage breast cancer, advanced non-small cell lung cancer (NSCLC), neoadjuvant therapy for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
